Hematopoietic stem cell transplantation for MDS.
Hematopoietic stem cell transplantation (HSCT) offers potentially curative therapy for patients with myelodysplastic syndromes (MDS). However, as the majority of patients with MDS are in the seventh or eighth decade of life, conventional transplant regimens have been used only infrequently, and only with the development of reduced-intensity conditioning has transplantation been applied more broadly to older patients. Dependent upon disease status at the time of transplantation, 30% to 70% of patients can be expected to be cured of their disease and survive long term. However, posttransplant relapse and graft-versus-host disease (GVHD) remain problems and further investigations are needed.
Bartenstein
Matthias
M
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., Seattle, WA 98109-1024, USA.
Deeg
H Joachim
HJ
D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D015897:Comorbidity; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D019190:Iron Overload / Q000209:etiology; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000235:genetics / Q000601:surgery* / Q000628:therapy; D018579:Patient Selection; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D018570:Risk Assessment; D016879:Salvage Therapy; D012720:Severity of Illness Index; D065227:Transfusion Reaction; D019172:Transplantation Conditioning / Q000379:methods; D016896:Treatment Outcome
D004791:Enzyme Inhibitors